Stockwatch: Turkeys and Thanksgiving
This article was originally published in Scrip
It will be Barack Obama next week, and not Mitt Romney, who pardons the National Thanksgiving Turkey in traditional US festive ceremony. The relief rally in stocks which followed the re-election of president Obama was as brief as the rally that accompanied the US employment report the previous week (scripintelligence.com, 7 November 2012). Nothing, it seems can prevent the market's decline as investors flee from risk as they seek to remove potential downsides from their portfolios in the run up to the end of the year.
You may also be interested in...
The Coronavirus outbreak makes its first dent into pharma's 2020 prospects as AstraZeneca admits possible impact, while could AbbVie's aesthetic plans raise the prospect of another GSK-style spin off?
Expensive acquisitions are in the spotlight during earnings season. The purchases of Kite and Celgene by Gilead and Bristol-Myers Squibb are not turning out to be what was written on the tin.
With Brexit and coronavirus depressing markets over the week, earnings season for life science companies shifted into a higher gear with a number of big companies reporting. In time, the effects of Brexit and 2019-nCoV are likely to subside, but the double-edge sword of biosimilar commercialization continues to rise from the full-year financial reports of Pfizer and Roche.